OVX033
/ Osivax
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 24, 2025
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Osivax | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease
October 01, 2024
OVX033, N-based T-cell broad-spectrum vaccine candidate against all sarbecovirus is safe and immunogenic in non-human primates
(ISIRV-OPTIONS XII 2024)
- No abstract available
June 20, 2024
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Active, not recruiting | Sponsor: Osivax | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease
January 19, 2024
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Osivax | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Novel Coronavirus Disease
January 01, 2024
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Osivax
Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
1 to 5
Of
5
Go to page
1